- Four and circular Anaplastic lymphoma kinase inhibitors
-
The invention belongs to the technical field of medicines, and particularly relates to a four-ring anaplastic lymphoma kinase inhibitor as shown in a general formula (I), or stereisomers, or pharmaceutically acceptable salts, esters or solvates of the inhibitor, wherein A1, A2, A3, M, X, Y, Q, R4, R5, R6, R7 and n are defined in the specification. The invention also relates to a preparation method of these compounds, pharmaceutical preparations and pharmaceutical compositions containing these compounds, and application of the compound or the stereisomers, or the pharmaceutically acceptable salts, esters or solvates of the compound in preparation of medicines for treating and/or preventing ALK-mediated cancer related diseases.
- -
-
Paragraph 0384; 0385; 0386; 0387
(2017/08/25)
-
- Four and circular Anaplastic lymphoma kinase inhibitors
-
The invention belongs to the technical field of medicine, and more specifically relates to a tetra-heterocyclic-fused anaplastic lymphoma kinase inhibitor represented by general formula (I), and pharmaceutically acceptable salts, stereisomers, esters, or solvates thereof, wherein A1, A2, A3, R1, R2, R3, R4, R5, R6, R7, M, X, and Y are defined by the patent specification. The invention also relates to preparation methods of the compounds above, pharmaceutic preparations and pharmaceutical compositions containing the compounds, and applications of the tetra-heterocyclic-fused anaplastic lymphoma kinase inhibitor, the pharmaceutically acceptable salts, the stereisomers, the esters, or the solvates in preparing medicines used for treating and/or preventing ALK mediated cancer related diseases.
- -
-
Paragraph 0252-0254
(2017/08/02)
-
- Four and ring kinase inhibitors
-
The invention belongs to the technical field of medicines and relates to a tetra-cyclo-kinase inhibitor shown in the general formula (I) and its pharmaceutically acceptable salt, stereisomer, ester or solvate. In the general formula (I), R1, R2, R3, R4, M, W, X, Y and Z are defined in the specification. The invention also relates to a preparation method of the compounds, a drug containing the compounds, and a use of the compounds and its pharmaceutically acceptable salt, stereisomer, ester or solvate in preparation of a drug for treating and/or preventing ALK-mediated cancer-related diseases.
- -
-
Paragraph 0224; 0225; 0226; 0227
(2017/07/01)
-